1. Cancer Drug Resistance: A Brief Overview from a Genetic Viewpoint
    José Rueff et al, 2016, Cancer Drug Resistance CrossRef
  2. Non-receptor Tyrosine Kinases Role and Significance in Hematological Malignancies
    Ana Azevedo et al, 2019, Tyrosine Kinases as Druggable Targets in Cancer CrossRef
  3. Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses, and drug–drug interactions
    C Arimany-Nardi et al, 2015, The Pharmacogenomics Journal CrossRef
  4. ABC Efflux Transporters and the Circuitry of miRNAs: Kinetics of Expression in Cancer Drug Resistance
    Bruno C. Gomes et al, 2020, International Journal of Molecular Sciences CrossRef
  5. MicroRNAs and Cancer Drug Resistance
    Bruno Costa Gomes et al, 2016, Cancer Drug Resistance CrossRef
  6. Drug Resistance-Related Competing Interactions of lncRNA and mRNA across 19 Cancer Types
    Haizhou Liu et al, 2019, Molecular Therapy - Nucleic Acids CrossRef
  7. The human organic cation transporter OCT1 and its role as a target for drug responses
    Nicolas Brosseau et al, 2019, Drug Metabolism Reviews CrossRef
  8. Identifying and Validating a Combined mRNA and MicroRNA Signature in Response to Imatinib Treatment in a Chronic Myeloid Leukemia Cell Line
    Steven Bhutra et al, 2014, PLoS ONE CrossRef
  9. Impact of Membrane Drug Transporters on Resistance to Small-Molecule Tyrosine Kinase Inhibitors
    Claudia Neul et al, 2016, Trends in Pharmacological Sciences CrossRef
  10. Organic Cation Transporters in Health and Disease
    Hermann Koepsell et al, 2020, Pharmacological Reviews CrossRef
  11. OCT1 and imatinib transport in CML: is it clinically relevant?
    D B Watkins et al, 2015, Leukemia CrossRef
  12. BCR-ABL V280G Mutation, Potential Role in Imatinib Resistance: First Case Report
    Ana P Azevedo et al, 2017, Clinical Medicine Insights: Oncology CrossRef
  13. MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: A meta-analysis
    N Louati et al, 2022, Journal of Oncology Pharmacy Practice CrossRef
  14. Gene expression profiling for targeted cancer treatment
    Anton Yuryev, 2015, Expert Opinion on Drug Discovery CrossRef
  15. Current trends in molecular diagnostics of chronic myeloid leukemia
    Raquel Vinhas et al, 2017, Leukemia & Lymphoma CrossRef
  16. hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia
    Islem Ben Hassine et al, 2017, Cancer Chemotherapy and Pharmacology CrossRef
  17. OCT-1 Expression in Patients with Chronic Myeloid Leukemia: A Comparative Analysis with Respect to Response to Imatinib Treatment
    Betul Bozkurt Bulakcı et al, 2022, Indian Journal of Hematology and Blood Transfusion CrossRef
  18. Association of SLC22A1,SLCO1B3 Drug Transporter Polymorphisms and Smoking with Disease Risk and Cytogenetic Response to Imatinib in Patients with Chronic Myeloid Leukemia
    Fatemeh Mohammadi et al, 2021, Laboratory Medicine CrossRef
  19. Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis
    Zhi-Ping Jiang et al, 2017, Pharmacogenomics CrossRef
  20. MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: a meta-analysis
    Bailing Zu et al, 2014, Pharmacogenomics CrossRef
  21. Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and chronic myeloid leukemia
    Gloria Ravegnini et al, 2016, Expert Opinion on Drug Metabolism & Toxicology CrossRef
  22. The multi-factorial nature of clinical multidrug resistance in cancer
    Yehuda G. Assaraf et al, 2019, Drug Resistance Updates CrossRef
  23. Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia
    Luciene Terezina de Lima et al, 2014, Medical Oncology CrossRef
  24. Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment
    Monika Jaruskova et al, 2017, Journal of Experimental & Clinical Cancer Research CrossRef
  25. OCT-1,ABCB1, andABCG2Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib
    Yeo-Kyeoung Kim et al, 2014, Chonnam Medical Journal CrossRef
  26. Dynamics of Expression of Drug Transporters: Methods for Appraisal
    Marta Gromicho et al, 2016, Cancer Drug Resistance CrossRef